Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma

Trial Profile

A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2019

At a glance

  • Drugs Clofarabine (Primary) ; Mitoxantrone (Primary) ; Cytarabine; Dexrazoxane; Rituximab
  • Indications Acute myeloid leukaemia; Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Acronyms MITCL
  • Most Recent Events

    • 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 11 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
    • 11 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top